Phylogenetic analysis revealed the co-circulation of four dengue virus serotypes in Southern Thailand

Hamel, Rodolphe; Surasombatpattana, Pornapat; Wichit, Sineewanlaya; Dauvé, Alexandra; Donato, Celeste; Pompon, Julien; Vijaykrishna, Dhanasekaran; Liégeois, Florian; Vargas, Ronald Enrique Morales; Luplertlop, Natthanej; Missé, Dorothée

doi:10.1371/journal.pone.0221179

Cited by 35 publications

(49 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Lao PDR, Asian I and Cosmopolitan genotypes have been co-circulating since at least 2017 and was still ongoing in 2019. Compared to a recent study in Thailand, our series identified different lineages within the DENV-2 Cosmopolitan genotype [43]. Indeed, in Thailand only the Cosmopolitan genotype/Lineage B was observed between 2015 and 2016.…”

Section: Plos Onecontrasting

confidence: 73%

“…Indeed, in Thailand only the Cosmopolitan genotype/Lineage B was observed between 2015 and 2016. As seen elsewhere, since 2008 the Lao clusters within the Asian I genotype have had different geographic origins and evolved over time as independent topotypes as is seen on other countries [4,43,50]. In a panel tested previously and in this study, the co-circulation of two or three clusters were observed in 2009-2010 (cluster 1, 2 and 3), in 2012 (clusters 3 and 5), in 2017 (clusters 4 and 6) and in 2018 (clusters 4 and 7).…”

Section: Plos Onementioning

confidence: 72%

“…DENV genotype co-circulation has already been depicted in Lao PDR for DENV-3 [5]. For DENV-2, the co-circulation of Asian I and Asian/American or Cosmopolitan genotypes has been documented in Thailand, Cambodia or Vietnam [43,50].…”

Section: Plos Onementioning

confidence: 94%

“…Observations of the presence of the Cosmopolitan genotype with the co-circulation of two different lineages detected as early as 2016, along with the circulation of several Asian I genotype clusters since 2008 support this hypothesis. Lao PDR shares a border with five countries where DENV circulation is highly active [1,43,49]. Exchanges between Lao PDR and its neighboring countries is increasing constantly especially with regards to commerce [4,5].…”

Section: Plos Onementioning

confidence: 99%

See 3 more Smart Citations

Rapid genotyping protocol to improve dengue virus serotype 2 survey in Lao PDR

Calvez¹,

Somlor²,

Viengphouthong³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Dengue fever is one of the major public health problems in Lao PDR. Over the last decade, dengue virus (DENV) epidemics were characterized by a novel predominant serotype accompanied by at least two other serotypes. Since 2008, DENV-2 circulated at a low level in Lao PDR but its epidemiologic profile changed at the end of 2018. Indeed, the number of confirmed DENV-2 cases suddenly increased in October 2018 and DENV-2 became predominant at the country level in early 2019. We developed a Genotype Screening Protocol (GSP) to determine the origin(s) of the Lao DENV-2 and study their genetic polymorphism. With a good correlation with full envelope gene sequencing data, this molecular epidemiology tool evidence the co-circulation of two highly polymorphic DENV-2 genotypes, i.e. Asian I and Cosmopolitan genotypes, over the last five years, suggesting multiple introductions of DENV-2 in the country. GSP approach provides relevant first line information that may help countries with limited laboratory resources to reinforce their capabilities to DENV-2 and to follow the epidemics progresses and assess situations at the regional level.

show abstract

Section: Plos Onecontrasting

confidence: 73%

Section: Plos Onementioning

confidence: 72%

Section: Plos Onementioning

confidence: 94%

Section: Plos Onementioning

confidence: 99%

See 2 more Smart Citations

Rapid genotyping protocol to improve dengue virus serotype 2 survey in Lao PDR

Calvez¹,

Somlor²,

Viengphouthong³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…An ideal dengue antiviral must significantly reduce the viral load within 70 h of illness onset to prevent disease progression to DHF or DSS [24]. Furthermore, the drug should inhibit all four DENV serotypes as these serotypes could co-circulate in endemic areas [25,26].…”

Section: Current Status Of Dengue Antiviral Developmentmentioning

confidence: 99%

Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus

Anasir

Ramanathan

Poh

2020

Viruses

View full text Add to dashboard Cite

Dengue virus (DENV) presents a significant threat to global public health with more than 500,000 hospitalizations and 25,000 deaths annually. Currently, there is no clinically approved antiviral drug to treat DENV infection. The envelope (E) glycoprotein of DENV is a promising target for drug discovery as the E protein is important for viral attachment and fusion. Understanding the structure and function of DENV E protein has led to the exploration of structure-based drug discovery of antiviral compounds and peptides against DENV infections. This review summarizes the structural information of the DENV E protein with regards to DENV attachment and fusion. The information enables the development of antiviral agents through structure-based approaches. In addition, this review compares the potency of antivirals targeting the E protein with the antivirals targeting DENV multifunctional enzymes, repurposed drugs and clinically approved antiviral drugs. None of the current DENV antiviral candidates possess potency similar to the approved antiviral drugs which indicates that more efforts and resources must be invested before an effective DENV drug materializes.

show abstract